Pharmaceutical care on one case of hypobrinogenemia induced by hemocoagulase

doi:10.12092/j.issn.1009-2501.2018.08.016

Abstract

Abstract:

AIM: To investigate the pharmaceutical care of patients with cirrhosis decompensated in the application of hemocoagulase. METHODS: By participating in the treatment of 1 case of cirrhosis with hypofibrinogenemia, clinical pharmacist conducted a pharmacy evaluation according to the evaluation criteria of the National Center for ADR Monitoring. The result indicated an ADR caused by the hemocoagulase. It is recommended to avoid using the relevant drugs and to perform pharmacological monitoring on the patient.RESULTS: Clinical pharmacist provided rational suggestions with professional knowledges, accepted by clinicians, timely and effective treatment of adverse drug reactions, so that patients can be discharged after effective treatment. CONCLUSION: Clinical pharmacists participate in the treatment process of patients with cirrhosis and carry out pharmacy services, which can provide reasonable and effective medication recommendations to ensure the safety of patients.

Key words: hemocoagulase, liver cirrhosis, hypofibrinogenemia, pharmaceutical care

CLC Number:

YANG Bo, SHI Dawei, ZHENG Zaoqian. Pharmaceutical care on one case of hypobrinogenemia induced by hemocoagulase[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 932-936.

References

［1］Li H, Huang Y, Wu T, et al. Effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities［J］. Drug Des Devel Ther, 2018, 12: 1385-1398.
［2］李海平, 黄录茂, 雍成明,等. 蛇毒血凝酶在颅脑手术病人中止血疗效观察［J］. 中国临床药理学与治疗学, 2010, 15(7): 786-787.
［3］注射用血凝酶安全性回顾研究协作组, 单爱莲. 外科手术中应用注射用血凝酶安全性多中心大样本回顾性调查［J］. 中国新药与临床杂志, 2011(12): 942-946.
［4］钱筠, 宁丰, 王景文. 奥美拉唑导致纤维蛋白原减少［J］. 药物不良反应杂志, 2010, 12 (6): 436-436.
［5］孟景晔, 骆子义, 朱惠敏,等. 蛇毒血凝酶引起低纤维蛋白原血症6例［J］. 中国输血杂志, 2014, 27(4): 446-447.
［6］王兆钺, 李建琴, 曹丽娟,等. 长期使用蛇毒血凝酶致低纤维蛋白原血症三例报告并文献复习［J］. 中华血液学杂志, 2014, 35(1): 50-52.
［7］王鸿利, 张利伟, 丁秋兰,等. 原发性纤溶症的诊断和鉴别诊断［J］. 实验与检验医学, 2008, 26(1): 2-4.
［8］李志林, 黄汉光, 邓恩平. 血浆D-二聚体水平与肝硬化患者病因、肝功能分级、并发症的关联分析［J］. 中国医学创新, 2017, 14 (30): 112-115.
［9］梁宗潮, 梁丹茹. 巴曲亭在胆道手术中的应用［J］. 临床肝胆病杂志, 2014(4): 360-362.
［10］崔亮亮, 孙东,石皎,等. 不同蛇毒类凝血酶制剂对纤维蛋白原的作用［J］.药物生物技术, 2014(1): 53-56.
［11］朱明启. 血凝酶在标准大骨瓣减压术中的止血效果［J］. 实用临床医药杂志, 2016, 20(3): 148-149.
［12］Zhou HB. Hypofibrinogenemia caused by hemocoagulase after colon polyps excision［J］. Am J Case Rep, 2017;18: 291-293.
［13］Wei NL, Jia YF, Wang X. Risk factors for postoperative fibrinogen deficiency after surgical removal of intracranial tumors［J］. Plos One, 2015, 10 (12): e0144551.

[1]	LIU Xiumei, GUO Qianqian, FANG Yuan, CHEN Nan, QI Qi. Pharmaceutical care of patients with antithrombotic therapy after transjugular intrahepatic portal shunt [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 556-560.
[2]	ZHANG Zhaowei, LI Zuojun, HUANG Jian, LI Shuangqing, HE YiLin. Exploring the outbreak point for clinical pharmacists to provide pharmaceutical care in nephrology department [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 184-188.
[3]	LI Jingjing, YU Yanxia, TANG Lian, ZHANG Jinkun, YU Qiang, SHANG Erning. Influence of clinical pharmaceutical care on medication compliance and treatment effect in Helicobacter pylori positive peptic ulcer outpatients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 199-204.
[4]	ZHU Xuting, HANG Yongfu. Clinical pharmacists' pharmaceutical care and practice in the department of nephrology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1174-1178.
[5]	WANG Lin, XU Wen-ke, ZHANG Wen, YANG Xiao-jun, WANG Wei-ping. Retrospective analysis of 90 cases of drug counseling online [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 162-166.
[6]	LIU Jun, XU Hang. Evaluation of warfarin anticoagulant management by clinic pharmacists on patients with cardiac valve surgery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1021-1024.
[7]	LIN Qi, DAI Wen-sen, GUO Li-jing. Approaches for clinical pharmacists to implement pharmaceutical care for bronchiectasis patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1238-1240.
[8]	LUO Song-mei, YE Wei-hong, HUA Jun-yan. Clinical pharmacists' participation in acute exacerbations of COPD therapy practice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1014-1018.
[9]	ZHANG Wei-ping, GAO Qin, LI Zheng-hong, SU Ai-rong, WU Ji-feng. Effects of liver cirrhosis on the expression of myosin heavy chain in rat myocardium [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1121-1125.
[10]	XU Xiao-bing, YANG Miao-fang, ZHU Ren-min. Advancement on the therapy of somatostatin on liver fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(6): 707-710.
[11]	LU Hai-ying, ZENG Zheng, TIAN Di, CUI Jian-jun, TIAN Guo-bao, TIAN Xiu-lan, YU Min, QIN Xiao-qin. Clinical significance of alpha-fetoprotein detection in HBV infectious related diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(8): 939-942.
[12]	SHI Shao-jun, CHEN Hua-ting, ZENG Fan-dian. Progress in research of pharmaceutical care [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(1): 1-4.